CPP Product directory

合集下载

首营资料目录(索取) -国外

生产批号、生产日期、有效期的格式
其
他
1、进口前必须按进口注册标准检验合格。
2、提供在“进口药品注册标准”上所使用的对照品/标准品。
3、大箱上下使用封箱带。
4、采购合同（含运输责任）
5、签署质量协议。
The first supply enterprise and product catalog
Project
2、Reference substance in the imported drug registration standards / standards.
3、Up and down the box sealing tape.
4、Procurement contracts (with responsibility for Transport)
Need to provide a blank bag
(Batch number, date of expiry / production)
In packaging
(If any)
Color draft (final version)
Large packing
Color draft (final version)
首营资料目录
项目
所需资料名称
备注
供
应
商
1、企业注册资料
2、药品生产许可证
3、GMP/CPP
产
品
1、本国产品批准证书
2、企业质量标准
3、进口药品注册证
药品补充申请批件
4、进口药品注册标准
5、条形码许可证明
6、商标使用许可
7、商品名批件
8、价格批件
9、企业出厂检验报告书
10、临床总结报告（中国市场）

CC++学习----使用C语言代替cmd命令、cmd命令大全

CC++学习----使⽤C语⾔代替cmd命令、cmd命令⼤全【开发环境】物理机版本：Win 7 旗舰版（64位）IDE版本：Visual Studio 2013简体中⽂旗舰版（cn_visual_studio_ultimate_2013_with_update_4_x86_dvd_5935081_Chinese-Simplified）【前⾔】cmd常⽤命令：calc：启动计算器notepad：打开记事本netstat -a:查看所有的端⼝tasklist：查看所有的进程d: 盘符切换dir(directory) 列出当前⽬录下的⽂件以及⽂件夹md (make directory) 创建⽬录rd (remove directory) 删除⽬录(带内容的⽂件或者⽂件夹不能直接删除，必须先删除⾥⾯，再删除外⾯)。

如果要删除⾮空⽬录，可以使⽤命令：rd /s xxxdir或者rd /s /q xxxdircd (change directory) 改变指定⽬录(进⼊指定⽬录)cd.. 退回到上⼀级⽬录cd\ 退回到根⽬录del (delete) 删除⽂件,删除⼀堆后缀名⼀样的⽂件*.txtexit 退出dos命令⾏cls (clear screen)清屏Win7中打开cmd窗⼝的⽅式：在当前路径下，按住shift键，⿏标右键：⼀、通过C语⾔代码来实现cmd命令⾏功能：这⾥⽤到了c语⾔中的⼀个库：#include<stdlib.h>1、打开记事本：cmd.cpp:#include<stdlib.h>void main() {system("notepad"); //System：执⾏系统的命令⾏}程序⼀运⾏，记事本就打开了：2、查看ip地址：#include<stdlib.h>void main(){system("ipconfig");system("pause"); //如果没有这⼀⾏代码，cmd窗⼝就会闪退}注：如果没有第04⾏的pause，cmd窗⼝就会闪退。

WHO CPP药品证明书-参考格式

Model certificate of a pharmaceutical productPlease refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than handwritten.Additional sheets should be appended, as necessary, to accommodate remarks and explanations.Certificate of a pharmaceutical product1This certificate conforms to the format recommended by the World Health OrganizationNo. of certificateExporting (certifying country):Importing (requesting country):1. Name and dosage form of the product:1.1. Active ingredient(s)2 and amount(s) per unit dose3:For complete composition including excipients, see attached4:1.2. Is this product licensed to be placed on the market for use in the exporting country?5 (yes/no) 1.3 Is this product actually on the market in the exporting country?If the answer to 1.2. is yes, continue with section 2A and omit section 2B.If the answer to 1.2 is no, omit section 2A and continue with section 2B6:2.A.1. Number of product licence7 and date of issue:2.A.2. Product licence holder (name and address):2.A.3. Status of product licence holder8: (Key in appropriate category as defined in note 8)2.A.3.1. For categories b and c the name and address of the manufacturer producing the dosage form is9:2.A.4. Is a summary basis for approval appended?10 (yes/no)2.A.5. Is the attached, officially approved product information complete and consonent with the licence?11 (yes/no/not provided)2.A.6. Applicant for certificate, if different from licence holder (name and address)12:2.B.1. Applicant for certificate (name and address):2.B.2. Status of applicant: (Key in appropriate category as defined in footnote 8)2.B.2.1. For categories (b) and (c) the name and address of the manufacturer producing the dosage form is:92.B.3. Why is marketing authorization lacking? (not required/not requested/under consideration/refused)2.B.4. Remarks13:3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? (yes/no/not applicable)14If not or not applicable, proceed to question 4.3.1. Periodicity of routine inspections (years):3.2. Has the manufacture of this type of dosage form been inspected? (yes/no)3.3 Do the facilities and operations conform to GMP as recommended by the World Health Organization?15 (yes/no/not applicable)144. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product16: (yes/no)If no, explain:Address of certifying authority:Telephone:Fax:Name of authorized person:SignatureStamp and dateExplanatory notes1.This certificate, which is in the format recommended by WHO, establishes the status of thepharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.e, whenever possible, International Nonproprietary Names (INNs) or nationalnonproprietary names.3.The formula (complete composition) of the dosage form should be given on the certificateor be appended.4.Details of quantitative composition are preferred but their provision is subject to theagreement of the product-licence holder.5.When applicable, append details of any restriction applied to the sale, distribution oradministration of the product that is specified in the product licence.6.Sections 2A and 2B are mutually exclusive.7.Indicate, when applicable, if the licence is provisional, or the product has not yet beenapproved.8.Specify whether the person responsible for placing the product on the market:a.manufactures the dosage form;b.packages and/or labels a dosage form manufactured by an independent company;orc.is involved in none of the above.9.This information can only be provided with the consent of the product-licence holder or, inthe case of non-registered products, the applicant. Non-completion of this sectionindicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product licence.If the production site is changed, the licence has to be updated or it is no longer valid.10.This refers to the document, prepared by some national regulatory authorities, thatsummarizes the technical basis on which the product has been licensed.11.This refers to product information approved by the competent national regulatoryauthority, such as Summary Product Characteristics (SPC)12.In this circumstance, permission for issuing the certificate is required from theproduct-licence holder. This permission has to be provided to the authority by theapplicant.13.Please indicate the reason that the applicant has provided for not requesting registration.a.the product has been developed exclusively for the treatment of conditions —particularly tropical diseases — not endemic in the country of export;b.the product has been reformulated with a view to improving its stability undertropical conditions;c.the product has been reformulated to exclude excipients not approved for use inpharmaceutical products in the country of import;d.the product has been reformulated to meet a different maximum dosage limit foran active ingredient;e.any other reason, please specify.14.Not applicable means the manufacture is taking place in a country other than that issuingthe product certificate and inspection is conducted under the aegis of the country of manufacture.15.The requirements for good practices in the manufacture and quality control of drugsreferred to in the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations, WHO Technical Report Series No. 823, 1992, Annex 1. Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on BiologicalStandardization (WHO Technical Report Series, No. 822, 1992, Annex 1).16.This section is to be completed when the product-licence holder or applicant conforms tostatus (b) or (c) as described in note 8 above. It is of particular importance when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.。

关键质量属性CQA和关键工艺参数CPP评估

工艺控制和/或GMP控制（例如：水的质量，环
境控制）工艺控制
110
生产工艺的操作参数
关键参数非关键参数
工艺参数
重要参数非重要参数
221如何定义CPP ？窄范Fra bibliotek（和/或难控制）
宽范围（和/或易控制）
关键的* 工艺中一个可调节的参数（可变的），需要在窄的
范围内进行维护，以保证不会影响到关键的产品质量属
219
关键质量属性判定矩阵
属性
测试
关键or非关键
鉴别
所有的鉴别
关键
物化性质性状
pH、熔点、折光率等
物理状态（例如：液体、固体）
可能关键也可能不关键基于API的物理性质和计划用途
关键
含量
纯度粒度微生物纯度
含量测试
关键
有机（HPLC）无机（硫酸化灰分、
炽灼残渣）残留溶剂重金属* 手性杂质（手性分析、旋光度）
粒度密度
总数内毒素
热原
关键
使用ICHQ6A决策树使用ICHQ6A决策树
晶型
晶型测试
使用ICHQ6A决策树
*如果工艺不能控制或是影响该属性也可能需要GMP控制
工艺控制orGMP控制 GMP控制
工艺控制和/或GMP控制基于药品
GMP控制或工艺控制（工
艺条件可能影响物理状态）
工艺控制
工艺控制
工艺控制
Drug Product 制药产品
Critical Parameters 关键参数
Critical Steps 关键步骤
API Critical Quality Attributes
API关键质量属性

CPP生产状况及专用料开发进展

CPP生产状况及专用料开发进展吴志生【摘要】聚丙烯流延膜(CPP)因具有生产速度快,薄膜透明性好,热封性优良等特点,在日用品和复合材料等领域得到了广泛应用.本文概况了聚丙烯流延膜的分类及生产工艺技术,介绍了国内生产厂商、设备和产能等生产情况.分析了国内专用料树脂开发状况,以及CPP对聚丙烯基础专用料树脂的要求.最后对聚丙烯流延膜的前景进行了展望,指出需要加快研究和开发步伐,在扩大生产量的同时,进一步提高产品档次.【期刊名称】《广州化工》【年(卷),期】2013(041)009【总页数】4页(P34-37)【关键词】聚丙烯流延膜;生产工艺;聚丙烯专用树脂【作者】吴志生【作者单位】中国石化扬子石油化工有限公司塑料厂,江苏南京210048【正文语种】中文【中图分类】TQ426.6聚丙烯薄膜按制法、性能和不同用途可分为聚丙烯流延膜(Cast Polypropylene film;CPP)、聚丙烯吹胀膜和双向拉伸聚丙烯薄膜三种。

聚丙烯流延膜是通过熔体流延骤冷生产的一种无拉伸、非定向的平挤薄膜。

与吹塑薄膜相比，其特点是生产速度快、产量高，薄膜透明性、光泽性、厚度均匀性优越，还具有良好的热封性、耐油性、耐蒸煮性，抗刮性和包装机械适用性好，同时由于是平挤薄膜，后续工序如印刷、复合等极为方便，因而广泛应用于纺织品、鲜花、食品、日用品的包装，同时也可用作高温蒸煮膜、复合膜内层热封材料和金属化基膜等［1－2］。

CPP 的生产有单层流延和多层共挤流延两种方式。

单层流延薄膜主要要求材料低温热封性能和挺度好。

多层共挤流延膜可分为热封层、支撑层、电晕层三层，在材料的选择上较单层膜宽，可单独选择满足各个层面要求的物料，赋予薄膜不同的功能和用途［3］。

1 聚丙烯流延膜分类聚丙烯流延膜可分为通用CPP(General CPP，简称GCPP)薄膜、金属化型CPP(Metalized CPP，简称MCPP)薄膜和蒸煮型CPP(Retort CPP，简称RCPP)薄膜。

cpp标准库

cpp标准库源：C++标准库的所有头⽂件都没有扩展名。

C++标准库的内容总共在50个标准头⽂件中定义，其中18个提供了C库的功能。

<cname>形式的标准头⽂件【<complex>例外】其内容与ISO标准C包含的name.h头⽂件相同，但容纳了C++扩展的功能。

在<cname>形式标准的头⽂件中，与宏相关的名称在全局作⽤域中定义，其他名称在std命名空间中声明。

在C++中还可以使⽤ name.h形式的标准C库头⽂件名。

C++标准库的内容分为10类：C1.语⾔⽀持 C2.输⼊/输出 C3.诊断 C4.⼀般⼯具 C5.字符串C6.容器 C7.迭代器⽀持 C8.算法 C9.数值操作 C10.本地化C1 标准库中与语⾔⽀持功能相关的头⽂件头⽂件描述<cstddef> 定义宏NULL和offsetof，以及其他标准类型size_t和ptrdiff_t。

与对应的标准C头⽂件的区别是，NULL是C++空指针常量的补充定义，宏offsetof接受结构或者联合类型参数，只要他们没有成员指针类型的⾮静态成员即可。

<limits> 提供与基本数据类型相关的定义。

例如，对于每个数值数据类型，它定义了可以表⽰出来的最⼤值和最⼩值以及⼆进制数字的位数。

<climits> 提供与基本整数数据类型相关的C样式定义。

这些信息的C++样式定义在<limits>中<cfloat> 提供与基本浮点型数据类型相关的C样式定义。

这些信息的C++样式定义在<limits>中<cstdlib> 提供⽀持程序启动和终⽌的宏和函数。

这个头⽂件还声明了许多其他杂项函数，例如搜索和排序函数，从字符串转换为数值等函数。

它与对应的标准C头⽂件stdlib.h不同，定义了abort(void)。

abort()函数还有额外的功能，它不为静态或⾃动对象调⽤析构函数，也不调⽤传给atexit()函数的函数。

cpp解释

今天在VC6.0中咕哝个程序，遇到如下提示：Cannot open precompiled header file:'Debug/password.pch' No such file or directory所谓pch，即p re c ompiled h eader你可以打开StdAfx.h，然后F7.看看正常没~或者：选择全部组建，试试看：不行的话往下看。

（貌视写的有点乱）在菜单的“工程”--“设置”里选定工程，如图选择Tab页，在红圈中把u改成c，确定，回到工程中再Ctrl+F7（Compile）一下，就能生产pch文件了，然后再改回上文设置。

参考资料：预编译头文件(一般扩展名为.PCH)，是把一个工程中较稳定的代码预先编译好放在一个文件(.PCH)里。

这些预先编译好的代码可以是任何的C/C++代码--甚至可以是inline函数，只它们在整个工程中是较为稳定的,即在工程开发过程中不会经常被修改的代码.。

为什么需要预编译头文件？一言以蔽之：提高编译速度。

一般地，编译器以文件为单位编译，如果修改了一工程中的一个文件则所有文件都要重新编译，包括头文件里的所有东西(eg.Macro宏、Preprocessor预处理)，而VC程序中，这些头文件中所包括的东西往往是非常大的,编译之将占很长的时间。

但它们又不常被修改，是较稳定的，为单独的一个小文件而重新编译整个工程的所有文件导致编译效率下降，因此引入了.PCH文件。

如何使用预编译头文件以提高编译速度?要使用预编译头文件，必须指定一个头文件(.H)，它包含我们不会经常修改的代码和其他的头文件，然后用这个头文件(.H)来生成一个预编译头文件(.PCH)VC默认的头文件就是StdAfx.h，因为头文件是不能编译的，所以我们还需要一个.CPP文件来作桥梁，VC默认的文件为StdAfx.cpp，这个文件里只有一句代码就是：＃include "StdAfx.h"。

c++ getcurrentdirectory函数

c++ getcurrentdirectory函数正文：'GetCurrentDirectory' 函数是一个 C++ 的标准库函数，用于获取当前工作目录的路径。

它位于 <filesystem> 头文件中，并且是C++17 版本之后引入的。

使用 'GetCurrentDirectory' 函数非常简单，只需传入一个参数，该参数为一个字符数组，指定存储当前工作目录路径的缓冲区的大小。

函数将返回当前工作目录的路径，并将其存储在传入的缓冲区中。

下面是一个示例代码，演示如何使用 'GetCurrentDirectory' 函数：```cpp#include <iostream>#include <filesystem>int main(){char buffer[FILENAME_MAX];std::filesystem::path currentPath =std::filesystem::current_path();std::string currentDirectory = currentPath.string();std::cout << 'Current directory: ' << currentDirectory << std::endl;return 0;}```在上面的代码中，我们首先定义了一个字符数组 `buffer`，它将用于存储当前工作目录的路径。

然后，我们使用`std::filesystem::current_path()` 函数获取当前工作目录的路径，并将其存储在 `currentPath` 变量中。

接下来，我们将`currentPath` 转换为字符串类型，并将其存储在`currentDirectory` 变量中。

最后，我们使用 `std::cout` 将当前工作目录的路径打印到控制台上。

自动售货机C++程序设计简版

自动售货机C++程序设计自动售货机C++程序设计简介自动售货机是一种智能化设备，可以为用户提供各种商品的购买服务。

本文将介绍如何使用C++语言设计一个简单的自动售货机程序。

程序结构类设计我们将使用面向对象的方式设计自动售货机程序。

在程序中，我们将创建以下几个类：1. 商品类 (Product)：用于表示售货机中的商品，包含名称、价格等属性。

2. 售货机类 (VendingMachine)：用于管理售货机的机制，包括商品的存储、购买过程等。

3. 用户类 (User)：用于表示用户，包含购买商品等操作。

类之间的关系在程序中，售货机类将包含商品类的对象，并与用户类进行交互。

用户可以通过售货机类购买商品。

类的实现商品类 (Product)首先，我们定义商品类，它包含以下成员变量：cppclass Product {private:std::string name; // 商品名称double price; // 商品价格public:// 构造函数Product(std::string n, double p) : name(n), price(p) {}// 获取商品名称std::string getName() {return name;}// 获取商品价格double getPrice() {return price;}};商品类有一个构造函数，用于初始化商品的名称和价格。

通过getName()和getPrice()方法可以获取商品的名称和价格。

售货机类 (VendingMachine)接下来，我们定义售货机类。

这个类将包含商品类的对象，并实现购买商品的过程。

cppclass VendingMachine {private:std::vector<Product> products; // 售货机中的商品列表public:// 添加商品void addProduct(Product product) {products.push_back(product);}// 购买商品bool buyProduct(std::string productName, double &change) {for (Product &p : products) {if (p.getName() == productName) {if (change >= p.getPrice()) {change -= p.getPrice();return true;} else {return false;}}}return false;}};售货机类有一个属性`products`，用于存储售货机中的商品列表。

c++ mkir用法

c++ mkir用法摘要：C++ mkdir用法教程：创建目录、删除目录、重命名目录1.C++ mkdir简介2.C++ mkdir函数用法a.创建目录b.删除目录c.重命名目录3.实例演示4.注意事项5.总结正文：C++ mkdir用法教程：创建目录、删除目录、重命名目录1.C++ mkdir简介C++ mkdir是C++标准库中的一个函数，用于操作目录。

目录操作在计算机编程中非常常见，尤其是在文件管理系统、文件传输等领域。

2.C++ mkdir函数用法C++ mkdir函数有以下三种用法：a.创建目录```cpp#include <iostream>#include <string>#include <filesystem>int main() {std::string dir_path = "example_directory";std::error_code ec;bool result = std::filesystem::create_directory(dir_path, ec);if (ec) {std::cerr << "创建目录失败：" << ec.message() << std::endl;return 1;}std::cout << "目录创建成功：" << dir_path << std::endl;return 0;}```b.删除目录```cpp#include <iostream>#include <string>#include <filesystem>int main() {std::string dir_path = "example_directory";std::error_code ec;bool result = std::filesystem::remove(dir_path, ec);if (ec) {std::cerr << "删除目录失败：" << ec.message() << std::endl;return 1;}std::cout << "目录删除成功：" << dir_path << std::endl;return 0;}```c.重命名目录```cpp#include <iostream>#include <string>#include <filesystem>int main() {std::string old_dir_path = "old_directory";std::string new_dir_path = "new_directory";std::error_code ec;bool result = std::filesystem::rename(old_dir_path, new_dir_path, ec);if (ec) {std::cerr << "重命名目录失败：" << ec.message() << std::endl;return 1;}std::cout << "目录重命名成功：" << old_dir_path << " 变为" << new_dir_path << std::endl;return 0;}```3.实例演示请参考上述代码实例，根据实际需求进行修改和调试。

WHO CPP药品证明书-参考格式

Model certificate of a pharmaceutical productPlease refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than handwritten.Additional sheets should be appended, as necessary, to accommodate remarks and explanations.Certificate of a pharmaceutical product1This certificate conforms to the format recommended by the World Health OrganizationNo. of certificateExporting (certifying country):Importing (requesting country):1. Name and dosage form of the product:1.1. Active ingredient(s)2 and amount(s) per unit dose3:For complete composition including excipients, see attached4:1.2. Is this product licensed to be placed on the market for use in the exporting country?5 (yes/no) 1.3 Is this product actually on the market in the exporting country?If the answer to 1.2. is yes, continue with section 2A and omit section 2B.If the answer to 1.2 is no, omit section 2A and continue with section 2B6:2.A.1. Number of product licence7 and date of issue:2.A.2. Product licence holder (name and address):2.A.3. Status of product licence holder8: (Key in appropriate category as defined in note 8)2.A.3.1. For categories b and c the name and address of the manufacturer producing the dosage form is9:2.A.4. Is a summary basis for approval appended?10 (yes/no)2.A.5. Is the attached, officially approved product information complete and consonent with the licence?11 (yes/no/not provided)2.A.6. Applicant for certificate, if different from licence holder (name and address)12:2.B.1. Applicant for certificate (name and address):2.B.2. Status of applicant: (Key in appropriate category as defined in footnote 8)2.B.2.1. For categories (b) and (c) the name and address of the manufacturer producing the dosage form is:92.B.3. Why is marketing authorization lacking? (not required/not requested/underconsideration/refused)2.B.4. Remarks13:3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? (yes/no/not applicable)14If not or not applicable, proceed to question 4.3.1. Periodicity of routine inspections (years):3.2. Has the manufacture of this type of dosage form been inspected? (yes/no)3.3 Do the facilities and operations conform to GMP as recommended by the World Health Organization?15 (yes/no/not applicable)144. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product16: (yes/no)If no, explain:Address of certifying authority:Telephone:Fax:Name of authorized person:SignatureStamp and dateExplanatory notes1.This certificate, which is in the format recommended by WHO, establishes the status of thepharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.e, whenever possible, International Nonproprietary Names (INNs) or national nonproprietarynames.3.The formula (complete composition) of the dosage form should be given on the certificate orbe appended.4.Details of quantitative composition are preferred but their provision is subject to theagreement of the product-licence holder.5.When applicable, append details of any restriction applied to the sale, distribution oradministration of the product that is specified in the product licence.6.Sections 2A and 2B are mutually exclusive.7.Indicate, when applicable, if the licence is provisional, or the product has not yet beenapproved.8.Specify whether the person responsible for placing the product on the market:a.manufactures the dosage form;b.packages and/or labels a dosage form manufactured by an independent company; orc.is involved in none of the above.9.This information can only be provided with the consent of the product-licence holder or, inthe case of non-registered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product licence. If the production site is changed, the licence has to be updated or it is no longer valid.10.This refers to the document, prepared by some national regulatory authorities, that summarizesthe technical basis on which the product has been licensed.11.This refers to product information approved by the competent national regulatory authority,such as Summary Product Characteristics (SPC)12.In this circumstance, permission for issuing the certificate is required from theproduct-licence holder. This permission has to be provided to the authority by the applicant.13.Please indicate the reason that the applicant has provided for not requesting registration.a.the product has been developed exclusively for the treatment of conditions —particularly tropical diseases — not endemic in the country of export;b.the product has been reformulated with a view to improving its stability under tropicalconditions;c.the product has been reformulated to exclude excipients not approved for use inpharmaceutical products in the country of import;d.the product has been reformulated to meet a different maximum dosage limit for anactive ingredient;e.any other reason, please specify.14.Not applicable means the manufacture is taking place in a country other than that issuing theproduct certificate and inspection is conducted under the aegis of the country of manufacture.15.The requirements for good practices in the manufacture and quality control of drugs referredto in the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations, WHO Technical Report Series No. 823, 1992, Annex 1. Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No.822, 1992, Annex 1).16.This section is to be completed when the product-licence holder or applicant conforms to status(b) or (c) as described in note 8 above. It is of particular importance when foreign contractorsare involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting partiesresponsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.欢迎您的下载，资料仅供参考！致力为企业和个人提供合同协议，策划案计划书，学习资料等等打造全网一站式需求。

c++路径使用方法

c++路径使用方法在C++中，可以使用以下方法来处理文件和目录路径：1.使用C风格的字符串：c复制代码char path[] = "/path/to/file.txt";2.使用C++风格的字符串（推荐）：cpp复制代码std::string path = "/path/to/file.txt";3.使用标准库中的文件路径类（std::filesystem）：cpp复制代码#include<filesystem>namespace fs = std::filesystem;fs::path path("/path/to/file.txt");4.使用C风格的字符串和文件操作函数：c复制代码#include<cstdio>#include<cstdlib>#include<cstring>#include<cerrno>#include<cstdio>#include<cstdlib>#include<cstring>#include<cerrno>#include<sys/stat.h>#include<sys/types.h>#include<dirent.h>#include<unistd.h>char *realpath(const char *path, char *resolved_path); // 获取绝对路径DIR *opendir(const char *path); // 打开目录struct dirent *readdir(DIR *dir); // 读取目录内容int closedir(DIR *dir); // 关闭目录使用示例：1.获取绝对路径：cpp复制代码char *resolved_path = realpath("/path/to/file.txt", NULL);if (resolved_path != NULL) {printf("Resolved path: %s\n", resolved_path);free(resolved_path); // 释放内存} else {perror("realpath"); // 打印错误信息}2.打开目录：cpp复制代码DIR *dir = opendir("/path/to/directory");if (dir != NULL) {// 读取目录内容...closedir(dir); // 关闭目录} else {perror("opendir"); // 打印错误信息}。

关键质量属性CQA和关键工艺参数CPP评估

关键工艺参数（CPP）关键质量属性（CQA）产品质量标准工艺/设备平面布局图设备清单自控系统描述（如适用）
文件用途明确风险评估的策略要求确认厂房设施、系统、设备的直接影响系
统保持风险分析与注册工艺的一致性
熟悉生产工艺、操作单元、中间控制点，支
持工艺风险评估的执行基于对生产工艺的理解及历史经验基于研发的数据明确法规的要求生产工艺/设备信息了解 230 生产工艺/设备信息了解自控系统信息了解
• 高：失效随时会被发现。 • 中：失效通常都能被发现。
• 低：失效不太可能被发现。
253
风险评价矩阵
RiskClass 风险级别
LowProbability 可能性低
HighSeverity 严重性高
RiskClass2 风险级别2
MediumSeverity 严重性中
RiskClass3 风险级别3
原辅料准备
混合
真空上料
混合
244
122
风险识别‐CQA
混合均一度
245
风险识别‐CPP
识别各个操作单元中影响关键质量属性的关键工艺参数：
体积时间
转速
CPP
246
123
风险识别矩阵
混合
StepsCriticalQualityAttributesIncludes 工序关键质量属性包括
NO.
CQA
StepsCriticalProcessParametersIncludes 工序关键工艺参数包括
工艺控制和/或GMP控制（例如：水的质量，环
境控制）工艺控制
110
生产工艺的操作参数
关键参数非关键参数
工艺参数

c++getsystemdirectory例子

c++getsystemdirectory例子C++是一种流行的编程语言，用于开发各种类型的应用程序。

在C++中，我们可以使用函数来获取操作系统的各种信息。

本文将介绍如何使用C++的`GetSystemDirectory`函数获取操作系统的系统目录，并提供了一个相关的例子。

首先，让我们了解一下`GetSystemDirectory`函数。

该函数属于Windows API，可用于获取操作系统的系统目录。

系统目录是操作系统安装文件的位置，其中包含了一些核心的系统文件。

在32位系统上，默认的系统目录是`C:\Windows\System32`，而在64位系统上，默认的系统目录是`C:\Windows\SysWOW64`。

要在C++中使用`GetSystemDirectory`函数，我们首先需要包含相应的头文件`windows.h`。

在代码中，我们需要定义一个字符数组或字符串来接收获取到的系统目录。

然后，我们使用`GetSystemDirectory`函数将系统目录的路径复制到该数组中。

以下是一个使用`GetSystemDirectory`函数获取系统目录的示例代码：```cpp#include <iostream>#include <windows.h>int main() {//定义一个字符数组来接收系统目录char systemDir[MAX_PATH];//使用GetSystemDirectory函数获取系统目录UINT result = GetSystemDirectory(systemDir, MAX_PATH); if (result > 0 && result < MAX_PATH) {std::cout << "系统目录: " << systemDir << std::endl; }else {std::cerr << "无法获取系统目录" << std::endl;}return 0;}```在上面的代码中，我们使用`MAX_PATH`宏定义来定义字符数组`systemDir`的大小，该宏定义在`windows.h`头文件中。

c++ linux编译命令

c++ linux编译命令
C++Linux编译命令是指在Linux系统下，使用C++语言进行程序开发时所需的编译命令。

下面是一些常用的C++ Linux编译命令： 1. g++命令：用于编译C++程序。

语法：g++ [options] file1.cpp file2.cpp ... -o output 选项说明：
- -o output：指定输出文件的文件名。

- -c：仅编译源文件，生成目标文件（.o文件）。

- -g：生成调试信息。

- -O：优化编译过程。

- -Wall：显示全部警告。

2. make命令：用于自动化编译。

语法：make [target]
选项说明：
- target：指定要编译的目标（默认为Makefile中的第一个目标）。

3. cmake命令：用于生成Makefile文件。

语法：cmake [options] source_directory
选项说明：
- -G：指定生成的Makefile文件类型。

- -D：设置变量的值。

4. gdb命令：用于调试程序。

语法：gdb [options] [executable-file [core-file or process-id]]
选项说明：
- -tui：启动GDB的文本模式界面。

- -q：禁止显示版权和欢迎信息。

- -x：执行指定的GDB脚本。

以上就是一些常用的C++ Linux编译命令，开发者们可以根据需要使用相应的命令，提高编译效率和程序质量。

酪蛋白磷酸肽-无定形磷酸钙促进牙再矿化的机制

酪蛋白磷酸肽-无定形磷酸钙促进牙再矿化的机制罗菁菁【摘要】In the physiological states, demineralization and remineralization of enamel is in the dynamic balance. When the environment changes, the balance can be broken. Demineralization not only led to morphological changes (such as opaque spot), but also the initial of caries. We should take effective measures to block this process, so that the direction of balance toword the remineralization. In the last decades, fluoride are widely used as an effective topical agent for the prevention of caries by promoting enamel remineralization. But the side-effects of fluoride can limiting its application. Recently, it has been founded that milk and cheese have the properties of anticariogenic, which attributed to the casein. Its tryptic digestion product of phosphopeptides (CPP) have the ability to bind amorphous calcium phosphate (ACP). When the phosphopeptides appling to the surface of teeth, this can delive ring the calcium and phosphate ions, and enhances remineralization, prevents demineralization and reduces caries development. In this review, the structure and the source of CPP, the blend of CPP and ACP, the properties of enhances remineralization and prevents demineralization, the current evidence supporting of CPP-ACP, the interaction of CPP-ACP with fluoride, and the influence of the subsequent resin adhesion are in details.%牙体在正常生理状态下处于脱矿和再矿化的动力平衡之中,当环境改变后,平衡被打破,脱矿和再矿化会向某一方向持续进行.脱矿不仅导致牙体形态学发生改变,也是龋病的开端,所以应该采取有力措施阻断这一过程,使其平衡向再矿化方向发展.以往以氟化物防龋并取得了较好的效果,却因不良反应使其应用受到了一定的限制.研究显示,牛奶和奶酪等奶制品也可发挥防龋效应,且此种效应主要与牛奶中所含的酪蛋白有关.酪蛋白经过酶消化后所得到的酪蛋白磷酸肽(CPP)结合无定形磷酸钙(ACP),应用于牙体表面可持续提供钙和磷酸根离子,促进牙体再矿化并抑制牙体脱矿.本文就CPP的来源和结构、CPP与ACP结合、CPP-ACP的抑制脱矿和促进再矿化作用、CPP-ACP作用的试验支撑、CPP-ACP与氟化物的相互作用、CPP-ACP对树脂粘接力的影响等研究进展作一综述.【期刊名称】《国际口腔医学杂志》【年(卷),期】2011(038)006【总页数】4页(P662-664,669)【关键词】酪蛋白磷酸肽;无定形磷酸钙;无定形钙氟磷;再矿化;防龋作用【作者】罗菁菁【作者单位】安徽医科大学附属口腔医院修复科合肥230032【正文语种】中文【中图分类】R781.05正常牙体的主要无机结构羟磷灰石晶体是含有多种微量成分的生物混晶，为六方晶系，微溶于水，易溶于酸，故在酸性条件下容易脱矿。

c++ mkir用法

在C++中，`mkdir` 函数用于创建一个新的目录。

下面是 `mkdir` 函数的基本用法：```cpp#include <iostream>#include <sys/stat.h>int main() {std::string directoryName = "new_directory";// 使用 mkdir 函数创建一个新目录int result = mkdir(directoryName.c_str(), 0777); // 第二个参数表示权限，这里使用 0777 表示最高权限if (result == 0) {std::cout << "Directory created successfully." << std::endl;} else {std::cout << "Failed to create directory." << std::endl;}return 0;}```上述代码中，我们首先包含了两个头文件：`<iostream>` 用于输入输出操作，`<sys/stat.h>` 用于使用 `mkdir` 函数。

然后，我们定义了一个字符串 `directoryName`，用于指定要创建的目录的名称。

接下来，使用 `mkdir` 函数创建一个新的目录。

`mkdir` 函数的第一个参数是要创建的目录的路径名，通过 `c_str()` 函数将 C++ 字符串转换为 C 字符串。

第二个参数是权限，这里使用 `0777` 表示最高权限。

最后，根据 `mkdir` 函数的返回值判断目录是否成功创建，并输出相应的结果。

需要注意的是，`mkdir` 函数在创建目录时需要有适当的权限，否则可能会失败。

另外，该函数在某些操作系统上也具有其他参数选项，例如递归创建目录等。

cmake 语句顺序

cmake 语句顺序CMake是一种跨平台的构建工具，用于自动化构建过程。

在使用CMake编写构建脚本时，需要按照一定的顺序编写语句，以确保构建过程的正确执行。

以下是一些常用的CMake语句顺序，供参考：1. cmake_minimum_required：指定所需的CMake的最低版本。

2. project：设置项目的名称。

3. set：设置变量，可以用于指定源文件、编译选项等。

4. include_directories：添加头文件搜索路径。

5. add_executable：添加可执行文件，指定源文件和依赖的库。

6. add_library：添加库文件，指定源文件。

7. target_link_libraries：指定可执行文件或库文件依赖的库。

8. add_subdirectory：添加子目录，用于构建子项目。

9. find_package：查找外部依赖的库。

10. install：安装生成的可执行文件或库文件。

下面是对每个语句进行详细说明：1. cmake_minimum_required：此语句指定所需的CMake的最低版本。

例如，cmake_minimum_required(VERSION 3.10)表示需要CMake版本大于等于3.10。

2. project：此语句设置项目的名称。

例如，project(MyProject)将项目命名为MyProject。

3. set：此语句用于设置变量。

可以用于指定源文件、编译选项等。

例如，set(SOURCES main.cpp)将变量SOURCES设置为main.cpp。

4. include_directories：此语句用于添加头文件搜索路径。

例如，include_directories(include)将include目录添加到头文件搜索路径中。

5. add_executable：此语句用于添加可执行文件。

需要指定可执行文件的名称、源文件及其依赖的库。

c++ cmake语法

C++和CMake是两个不同的概念。

C++是一种编程语言，而CMake是一个跨平台的自动化建构系统，用于控制软件编译过程。

CMake使用一种名为CMakeLists.txt的配置文件来描述构建过程。

这个文件包含了CMake的命令，用于指定如何构建你的项目。

CMakeLists.txt文件通常包含以下几种类型的命令：
•add_executable：用于指定要构建的可执行文件。

•add_library：用于指定要构建的库。

•target_include_directories：用于指定目标应包含的目录。

•target_compile_options：用于指定目标应使用的编译选项。

•find_package：用于查找并链接外部库。

在这个例子中，我们首先指定了CMake的最小版本要求，然后设置了项目的名称。

接着，我们使用find_package命令来查找Boost库，并将其包含在项目中。

最后，我们使用add_executable命令来构建一个名为my_program的可执行文件，并使用target_include_directories和target_compile_options命令来指定其包含的目录和编译选项，使用target_link_libraries命令来链接所需的库。

相关主题

1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。

1 Myers-Briggs Type Indicator ® and Form-M Self–Scorable Edition6129-MForm M Self Scorable Booklet &Introduction to Type ® (English Version ) .............................. ￥3106129SIM-M Form M Self Scorable Booklet &Introduction to Type ® (Chinese Simplified ) ........................... ￥2806129TRD-M Form M Self Scorable Booklet &Introduction to Type ® (Chinese Traditional ).......................... ￥3006139 –M Form M Self Scorable Booklet &Introduction to Type ® in Organizations (English Version )……￥3406139SIM-M Form M Self Scorable Booklet &Introduction to Type ® in Organizations (Chinese Simplified ) ￥2706139TRD-M Form M Self Scorable Booklet & Introduction to Type®in Organizations (Chinese Traditional) ......................... ￥285MBTI Form-M Reports (Only available online)MBTI ® Profile ReportEnglish Version+ Introduction to Type261145- P (Colour Print)................................................ ￥350 261145- P (in PDF Format) ............................................ ￥270English Version+ Introduction to Type in Org.261145- P (Colour Print) .............................................. ￥380 261145- P (in PDF Format) ........................................... ￥300Simplified Chinese Version + Introduction to Type661145SIM-P (Colour Print) ............................................... ￥340 661145SIM-P (in PDF Format) ............................................. ￥260Simplified Chinese Version + Introduction to Type in Org.661145SIM -P (Colour Print) ................................................ ￥340 661145SIM-P (in PDF Format) ............................................... ￥260Traditional Chinese Version + Introduction to Type661145TRD-P (Colour Print)................................................ ￥355 661145TRD-P (in PDF Format).............................................. ￥275Traditional Chinese Version + Introduction to Type in Org.661145TRD-PO (Colour Print) ................................................ ￥365 661145 TRD-PO (in PDF Format) ............................................ ￥285MBTI ® Interpretive ReportEnglish Version+ Introduction to Type261144- IR (Colour Print)................................................ ￥405 261144- IR (in PDF Format) ............................................ ￥325English Version+ Introduction to Type in Org.261144- IR (Colour Print) ............................................... ￥435 261144- IR (in PDF Format) ........................................... ￥355Simplified Chinese Version + Introduction to Type661144SIM-IR (Colour Print)................................................ ￥410 661144SIM-IR (in PDF Format) ............................................ ￥330Simplified Chinese Version + Introduction to Type in Org.661144 SIM-IR (Colour Print)................................................ ￥410 661144 SIM-IR (in PDF Format) ............................................ ￥330Traditional Chinese Version + Introduction to Type661144TRD-IR (Colour Print) ￥430 661144TRD-IR (in PDF Format) ............................................ ￥350Traditional Chinese Version + Introduction to Type in Org.661144 TRD-IR (Colour Print)................................................ ￥440 661144 TRD-IR (in PDF Format) ............................................. ￥3602MBTI ® Interpretive Report for Org.English Version+ Introduction to Type261146- IRO (Colour Print) ................................................￥440 261146- IRO (in PDF Format).............................................￥360English Version+ Introduction to Type in Org261146- IRO (Colour Print) ................................................￥470261146- IRO (in PDF Format) ............................................￥390Simplified Chinese Version + Introduction to Type661146 SIM-IRO (Colour Print) ...............................................￥450 661146 SIM-IRO (in PDF Format) ...........................................￥370Simplified Chinese Version + Introduction to Type in Org.661146SIM-IRO (Colour Print) ................................................￥450 661146 SIM-IRO (in PDF Format).............................................￥370Traditional Chinese Version + Introduction to Type661146 TRD-IRO (Colour Print) ................................................￥465 661146 TRD-IRO (in PDF Format).............................................￥385Traditional Chinese Version + Introduction to Type in Org.661146TRD-IRO (Colour Print) ................................................￥475 661146TRD-IRO (in PDF Format) .............................................￥395261248 C MBTI ® Team Report (Colour Print ) ..................................￥275 261248 MBTI ® Team Report (in PDF Format ) ..............................￥195 261182 C MBTI ® Work Styles (Colour Print ) ...................................￥280 261182 MBTI ® Work Styles (in PDF Format ) ................................￥200 262153 C MBTI ® Career Report (Colour Print ) ................................￥200 262153 MBTI ® Career Report (in PDF Format ) ............................￥120 261189 C MBTI ® Communication Report (Colour Print ) .................￥280 261189 MBTI ® Communication Report (in PDF Format ) ..............￥200MBTI Form-Q Reports (Only available online)English Report267149C MBTI ® Step II Interpretive (Colour) + Introduction to Type ￥540267149MBTI ® Step II Interpretive (PDF)+ Introduction to Type ……………………………………………………………….￥460 267149 C+ITTOR MBTI ® Step II Interpretive (Colour)+ Introduction to TypeIn Org ……………………………………………………￥570267149 +ITTOR MBTI ® Step II Interpretive (PDF)+ Introduction to TypeIn Org ……………………………………………………￥490267147 C MBTI® Step II Profile Report (colour)+ Introduction to Type ……………………………………………………………….￥430 267147 MBTI® Step II Profile Report (PDF) + Introduction to Type ……………………………………………………………….￥350 267147 C+ITTOR MBTI® Step II Profile Report (colour) + Introduction toType in Org……………………………………………..￥460267147 +ITTOR MBTI® Step II Profile Report (PDF) + Introduction toType in Org. …………………………………………….￥380261001 MBTI® Complete…………………………………………..￥450Simplified Chinese ReportMBTI ® Step II Interpretive (Colour) + Introduction to Type ............. ￥545 MBTI ® Step II Interpretive(PDF)+Introduction to Type ................... ￥465 MBTI ® Step II Interpretive (Colour) + Introduction to Type In Org….￥545 MBTI ® Step II Interpretive (PDF) + Introduction to Type In Org ……￥4653 Traditional Chinese ReportMBTI ® Step II Interpretive (Colour) + Introduction to Type .............. ￥560MBTI ®Step II Interpretive(PDF)+Introduction to Type ....................￥480 MBTI ®Step II Interpretive (Colour) + Introduction to Type In Org….￥570 MBTI ® Step II Interpretive (PDF) + Introduction to Type In Org ……￥490MBTI® Resource Material6129 Introduction to Type ® (English Version ) .............................. ￥160 6129 SIM Introduction to Type ® (English Version ) .............................. ￥1456129 TRD Introduction to Type ® (English Version )............................... ￥150 6139 Introduction to Type ® in Organizations (English) ..............￥190 6139SIM Introduction to Type ®in Organizations (Chinese Simplified).. ￥1456139TRD Introductionto Type ® in Organizations (Chinese Traditional).￥160 6998 Introduction to Type ® & Teams (English).......................... ￥2006998SIM Introductionto Type ® & Teams (Chinese Simplified) ............. ￥170 6998 TRD Introduction to Type ® & Teams (Chinese Traditional) ............ ￥1756111 Manual (1998) – (3rd Ed.) ..........................................￥1,760 4178 Understanding your MBTI ® Step II Results................... ￥235 6741 MBTI ®Step II Manual ................................................ ￥1,640 5105 Enhancing Leadership Effectiveness through Psychological Type ....................................... ￥2605111 Exercises for Differentiating MBTI ®Type ...................... ￥385 7270 Gifts Differing ......................................................... ￥245 6180 In the Grip .................................................................... ￥2006199 Introduction to Type ® & the 8 Jungian Functions.......... ￥200 6902 Introduction to Type ®& Careers................................... ￥200 6904 Introduction to Type ®& College ....................................￥200 6159 Introduction to Type ® & Coaching ................................. ￥2006189 Introduction to Type ® & Communications .....................￥200 6239 Introduction to Type ®& Conflict....................................￥200 6966 Introduction to Type ®& Change ................................... ￥2006186 Introduction to Type ® & Decision Making .....................￥200 6862 Introduction to Type ®Dynamics & Development .......... ￥200 6169 Introduction to Type ® & Emotional Intelligence ............. ￥2006185 Introduction to Type ®& Innovation………………….. ￥2006176 Introduction to Type ® & Leadership .............................. ￥2006187Introduction to Type ® & Learning ........................... ￥2003001 Looking at Type™ (4th Ed.) .......................................... ￥150 3105 Looking at Type™: The Fundamentals ............................ ￥170 3115 Looking at Type™ and Learning Styles ........................ ￥170 3120 Looking at Type™ and Spirituality ................................ ￥170 3110 Looking at Type™ in the Workplace ............................. ￥1706961 MBTI ®Career Report Users Guide ..............................￥500 6230 MBTI ® Conflict Management Program ......................￥3,925 6960 MBTI ® Team Building Workshop Kit ..........................￥3,925 6173 Type Tables International ..................................... ￥12206174 MBTI ®Type Tables for Occupation ........................... ￥1,5306175 Measuring Results of MBTI ® Training ..........................￥325 7295 People Types and Tiger Stripes (3rdEd.) .....................￥315 7278 Please Understand Me ................................................. ￥220 5110 Shape Up Your Program .............................................. ￥465 6150 The Leadership Advantage Training Program ........... ￥3,8805Simplified Chinese ReportsFIRO-B ®Profile Report (PDF) + Introduction to the FIRO-B ®...... ￥245FIRO-B ® Interpretive Report (PDF) + Introduction to the FIRO-B ® ￥280Traditional Chinese ReportFIRO-B ® Profile Report (PDF) + Introduction to the FIRO-B ®...... ￥270 FIRO-B ® Interpretive Report (PDF) + Introduction to the FIRO-B ® ￥305Resource Material2225 FIRO-B ® Technical Guide ............................................ ￥820 2209 Introduction to the FIRO-B ® ......................................... ￥200 2209sim Introduction to the FIRO-B ®(Simplified) ....................... ￥135 2209TRD Introduction to the FIRO-B ®(Traditional) ...................... ￥150 2209sim-F Introduction to the FIRO-B ® and SS (Simplified) ......... ￥260 2209TRD-FIntroduction to the FIRO-B ® and SS (Simplified) ......... ￥280 2219 Introduction to the FIRO-B ® in Organizations ............... ￥200 2191 Psychometric Properties of the FIRO-B ® ..................... ￥605 0783 Clinical Interpretation of FIRO-B ® ................................ ￥725 2220 Participating in Teams - Using your FIRO-B ® Results...￥200 2502 FIRO-B ® Business Technical Guide…………………… ￥870 2260DVD FIRO-B ® Feedback DVD……………………………….. ￥85CPI ™ 434 (California Psychological Inventory™)Forms and Reports 1973A CPI Test Booklets (pkt of 10) ....................................... ￥650 1978 Scannable Answer Sheet (pkt of 25)............................ ￥375 10127 Profile Report (B/W) ................................................... ￥245210127Profile Report (PDF) .................................................... ￥165 10128 Narrative Report (B/W) ................................................ ￥400210128Narrative Report (PDF) ................................................ ￥320 10129 Configural Analysis Report (B/W) ................................ ￥470210129Configural Analysis Report (PDF) ................................ ￥390Resource Material1971 CPI™ Manual ........................................................... ￥1,480 7294 Practical Guide to CPI™ Interpretation (3rd Ed.) ....... ￥1,360CPI 260™Reports1931 User’s Guide to the Coaching Report for Leaders ....... ￥645 1921 CPI 260TM Manual ..................................................... ￥1,425 1928 CPI 260TM Client Feedback Guide for Interpretation .... ￥660 1937 CPI 260TM Coaching Report for Leaders Adv. ............ ￥795 219250C Client Feedback Report (Colour) ................................. ￥280219250Client Feedback Report (PDF) ..................................... ￥200 219350C CoachingReport for Leaders (Colour) ......................... ￥420 219350Coaching Report for Leaders (PDF) ............................ ￥340 219550C CombinedClient/Coaching Report (Colour) ................. ￥560 219550 Combined Client/Coaching Report (PDF) .................... ￥480Strong Interest Inventory ®Forms and Reports 8511 Combined Item/Answer Booklets (pkt of 25) (scannable) ................................................. ￥37546Trademarks® MBTI, Myers-Briggs Type Indicator, and Introduction to Type areregistered trademarks of the Myers-Briggs Type Indicator Trust in the US and other countries ®Strong Interest Inventory is a registered trademark of CPP Inc. ® CPI, CPI 260 and FIRO-B are registered trademarks of CPP Inc TMStrong logo, California Psychological Inventory, CPI, CPI 260, FIRO-B, the FIRO-B logo and the TKI logo are trademarks of CPP Inc TMAPP, the APP logo, Australian Psychologists Press, and Asianic Psychologists Press are trademarks of APP TMLooking at Type is a trademark of CAPT Terms and Conditions PaymentAll prices shown are in RMB and are subject to change without notice. Discounts are available for large volume orders. Payment should be made in RMBby cheque or banker’s draft to “北京诺华仕企业管理顾问有限公司” by Bank Transfer to: 公司名称：北京诺华仕企业管理顾问有限公司开户银行：中国银行北京霄云路支行银行账号：808912088208092001Or in cash in person at our offices during normal working hours.DeliveryOrders will be despatched after receipt of full payment. Express courier delivery is available (at additional cost). We will inform you if for any reason the item(s) you requested are unavailable.89145 Standard Profile Report (Colour) .................................. ￥175289145 Standard Profile Report (PDF) ....................................... ￥9589147 High School Profile Report (Colour) ............................. ￥175289147 High School Profile Report (PDF) .................................. ￥9589144 Combined Standard Profile and Interpretive Report (Colour) ……………………………………………………………….￥220289144 Combined Standard Profile and Interpretive Report (PDF) ............................................................... ￥14089151 Combined High School Profile and Interpretive Report (Colour) ............................................................ ￥220289151 Combined High School Profile and Interpretive Report (PDF) ............................................................... ￥140289246 C Strong & MBTI Career Report (Colour) ........................ ￥235289246 Strong & MBTI Career Report (PDF) ........................... ￥155284108 C Strong Profile (Colour) ................................................. ￥175284108 Strong Profile (PDF) ....................................................... ￥95284105 C Strong High School Profile (Colour) ............................. ￥175284105Strong High School Profile (PDF) .................................. ￥95284104 C Strong Profile & Interpretive Report (Colour)................ ￥220 284104 Strong Profile & Interpretive Report (PDF) ................... ￥140 284210 C Strong High School Profile & Interpretive Report (Colour) .................................................................................... ￥220284210 Strong High School Profile & Interpretive Report (PDF)￥140Resource Material 8501 Strong Applications and Technical Guide ................. ￥1,4058401 Strong Interest Inventory Manual .............................. ￥1,1058403 Strong Interest Inventory User’s Guide ........................ ￥4608432 Where Do I Go Next? ................................................... ￥140Parker Team Player4900 Parker Team Building Program Facilitator’s Guide ...... ￥2,650 4913 Parker Team Player Survey ........................................... ￥2054916 Parker Team Player Survey Styles of Another Person ... ￥175Thomas-Kilmann Conflict Mode InstrumentForms and Reports4813 SIM TKI – Self Scorable ...................................................... ￥145 4813 TRD TKI – Self Scorable ...................................................... ￥1604813 TKI – Self Scorable ...................................................... ￥240248248C Profile and Interpretive Report (Colour) ....................... ￥225248248 Profile and Interpretive Report (PDF) ........................... ￥145Resource Material 4800 Conflict Workshop Facilitator’s Guide ....................... ￥2,7504816 Introduction to Conflict Management ............................ ￥2054818 Introduction to Conflict & Teams .................................. ￥205Others661500ALLT Think Box .............................................................. ￥1,300661500TT Think Box Team(10) ................................................ ￥1,400661500TT Think Box Team(up to 10) ...................................... ￥17,5004852 WEP ........................................................................... ￥2107 8ORDER FORMIn placing this order, I agree to the Terms & Conditions specified in Management Development Services Ltd.’s current Product DirectoryAuthorisingSignature………………………………………………………...........YOUR DETAILS Please write in BLOCK capitalsName: ................................................................. Title: ………………………………………………… Organisation: ………………………………………. Address: ……………………………………………. ……………………………………………………….. Tel: ……………………. Fax: ……………………... E-mail: ……………………………………………….Post To: (if different to billing address)Name: ................................................................. Title: ………………………………………………… Organisation: ………………………………………. Address: ……………………………………………. ……………………………………………………….. Tel: ……………………. Fax: ……………………... E-mail: ……………………………………………….MDS BeijingRoom 705, Towercrest Plaza,No. 3 Mai Zi Dian Xi Road, Chao Yang District, Beijing 100016, ChinaTel: (86 10) 6463 0800 Fax: (86 10) 6463 0900E-mail: mds@Please complete this form and fax to MDS Beijing, Fax Number: (86 10) 6463 0900OR order by telephone (86 10) 6463 0800 or email mds@For the purchase of Test Forms (and reports) only, the name of the qualified purchaser must be supplied.Name of qualified purchaser: …………………………………………………………………………………………..Tel: ……………………………….. Fax: ………………………………. E-mail:…………………………………….the test instrument(s) in question. You acknowledge that beyond this limited use license, CPP, IPAT and MDS Ltd. reserve all rights to these test instruments and other publications under U.S. and international copyright and trademark laws.。